Lilly Gets EUA For Antibody Cocktail It Says Might Target Variants

By Kelly Lienhard / February 9, 2021 at 10:42 PM

FDA on Tuesday night (Feb. 9) granted emergency use authorization for a combination of monoclonal antibodies from Eli Lilly, bamlanivimab and etesevimab, to treat patients who experience mild to moderate COVID-19 symptoms and are at risk of severe adverse health effects or hospitalization.


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.